©The Author(s) 2022.
World J Clin Cases. Jun 16, 2022; 10(17): 5606-5619
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5606
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5606
Table 1 General features of patients with hepatic epithelioid hemangioendothelioma
| General feature | No. of patients | % |
| Presence of symptoms, n = 254 | ||
| Asymptomatic | 69 | 27.2 |
| Symptomatic | 185 | 72.8 |
| Epigastric pain | 99 | 39.0 |
| Hepatosplenomegaly | 39 | 15.4 |
| Inappetence | 34 | 13.4 |
| Abdominal distension | 31 | 12.2 |
| Weight loss | 27 | 10.6 |
| Fatigue | 26 | 10.2 |
| Epigastric discomfort | 25 | 9.8 |
| Hydrothorax and ascite | 18 | 7.1 |
| Fever | 12 | 4.7 |
| Jaundice | 24 | 9.4 |
| Thoracalgia and humeral back pain | 20 | 7.9 |
| Nausea and vomiting | 10 | 3.9 |
| Edema | 8 | 3.1 |
| Cough and expectoration | 9 | 3.5 |
| Abdominal mass | 2 | 0.8 |
| Hematemesis and melena | 2 | 0.8 |
| Intrahepatic involvement type, n = 197 | ||
| Multinodular type (including diffuse type) | 168 | 85.3 |
| Mononodular type | 29 | 14.7 |
| Type of involvement, n = 197 | ||
| Intrahepatic involvement | 129 | 65.5 |
| Extrahepatic involvement | 68 | 34.5 |
| Lung | 44 | 22.3 |
| Lymph node | 11 | 5.6 |
| Bone | 13 | 6.6 |
| Peritoneum | 7 | 3.6 |
| Spleen | 10 | 5.1 |
| Pleura | 4 | 2.0 |
| Omentum | 2 | 1.0 |
| Liver function, n = 157 | ||
| Normal | 89 | 56.7 |
| Abnormal | 68 | 43.3 |
| Elevated ALT in U/L | 40 | 25.5 |
| Elevated AST in U/L | 40 | 25.5 |
| Elevated TBIL in μmol/L | 24 | 15.3 |
| Elevated ALP in U/L | 43 | 27.4 |
| Elevated GGT in U/L | 32 | 20.4 |
| Tumor markers | ||
| Elevated AFP in ng/mL | 8/171 | 4.7 |
| Elevated CEA in ng/mL | 7/130 | 5.4 |
| Elevated CA19-9 in U/mL | 13/135 | 9.6 |
| Elevated CA125 in U/mL | 14/53 | 26.4 |
| Plain CT scan, n = 198 | ||
| Low density lesions | 195/198 | 98.6 |
| High density or uneven density lesions | 3/198 | 1.4 |
| Calcification | 30/198 | 15.2 |
| Capsular retraction | 34/198 | 17.2 |
| Confluent masses | 42/198 | 21.2 |
| Contrast-enhanced CT, n = 163 | ||
| Tumor edge enhancement | 138/163 | 84.7 |
| Tumor edge without enhancement | 25/163 | 15.3 |
| Target sign | 33/163 | 20.2 |
| Lollipop sign | 19/163 | 11.7 |
| Immunohistopathological markers | ||
| FVIII-RAg | 117/118 | 99.2 |
| CD34 | 215/218 | 98.6 |
| CD31 | 171/173 | 98.8 |
| Vimentin | 94/95 | 98.9 |
| SMA | 12/27 | 44.4 |
| Desmin | 0/13 | NA |
| Hepatocyte | 8/58 | 13.8 |
| CK | 38/81 | 46.9 |
| EMA | 6/34 | 17.6 |
| AFP | 0/34 | NA |
| CEA | 0/11 | NA |
| S-100 | 1/33 | 9.1 |
| D2-40 | 7/11 | 63.6 |
| Genetics | ||
| YAP1-TFE3 | 3/4 | 75.0 |
| WWTR1-CAMTA1 | 3/5 | 60.0 |
- Citation: Zhao M, Yin F. Hepatic epithelioid hemangioendothelioma: Clinical characteristics, diagnosis, treatment, and prognosis. World J Clin Cases 2022; 10(17): 5606-5619
- URL: https://www.wjgnet.com/2307-8960/full/v10/i17/5606.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i17.5606